<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902020000100019</article-id>
<article-id pub-id-type="doi">10.29262/ram.v67i1.701</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efectividad del omalizumab en el control del asma grave no controlada en Latinoamérica. Revisión sistemática exploratoria y metaanálisis]]></article-title>
<article-title xml:lang="en"><![CDATA[The effectiveness of omalizumab in the control of severe uncontrolled asthma in Latin America. An exploratory systematic review and meta-analysis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Miranda]]></surname>
<given-names><![CDATA[Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,ALZAK Foundation  ]]></institution>
<addr-line><![CDATA[Bolívar ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<volume>67</volume>
<numero>1</numero>
<fpage>19</fpage>
<lpage>24</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902020000100019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902020000100019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902020000100019&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes:  El omalizumab es eficaz en el tratamiento del asma alérgica persistente grave no controlada con el tratamiento con betaagonistas de acción prolongada/corticoides inhalados en dosis alta.  Objetivo:  Realizar una revisión sistemática exploratoria y metaanálisis de estudios con omalizumab en Latinoamérica.  Métodos:  Se realizó una búsqueda de estudios de vida de real realizados en Latinoamérica sobre la efectividad de omalizumab en el control del asma. Se estimó la media de la efectividad agregada del omalizumab en el control del asma, utilizando un modelo de efectos aleatorios.  Resultados:  Se identificaron nueve estudios observacionales abiertos no controlados, que incluyeron 1118 pacientes con asma grave no controlada. La media de la efectividad agregada estimada del omalizumab en el buen control de asma grave fue de 80.6 %, en los niños fue de 83.4 % y en los adultos de 78.9 %.  Conclusiones:  La media de la efectividad agregada estimada de omalizumab en el control del asma alérgica grave fue superior a 78 %. Se requieren estudios controlados aleatorizados para establecer la eficacia y efectividad del fármaco en el control de asma grave y en los diferentes subgrupos por nivel de eosinófilos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background:  Omalizumab is effective in the treatment of severe persistent allergic asthma that is not controlled with long-acting beta-agonists/ high-dose inhaled corticosteroids.  Objective:  To conduct a systematic exploratory review and meta-analysis of studies with omalizumab in Latin America.  Methods:  A search of real-life studies on the effectiveness of omalizumab in asthma control conducted in Latin America was carried out. The average of the aggregate effectiveness of omalizumab in asthma control (Pooled Analysis) was estimated by using a random effects model.  Results:  Nine open uncontrolled observational studies were identified; these studies included a total of 1 118 patients with severe uncontrolled asthma. The average of the estimated aggregate effectiveness of omalizumab in the good control of severe asthma was of 80.6 % in children and 78.9 % in adults.  Conclusions:  The average of the estimated aggregate effectiveness of omalizumab in the control of severe asthma in both children and adults in Latin America was over 78 %. Randomized controlled studies are required in order to establish the efficacy and effectiveness of omalizumab in the control of severe asthma and in the different subgroups by level of eosinophils.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Omalizumab]]></kwd>
<kwd lng="es"><![CDATA[Asma severa]]></kwd>
<kwd lng="es"><![CDATA[Control de asma]]></kwd>
<kwd lng="en"><![CDATA[Omalizumab]]></kwd>
<kwd lng="en"><![CDATA[Severe asthma]]></kwd>
<kwd lng="en"><![CDATA[Asthma control]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ocampo]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Gaviria]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of asthma in Latin America. Critical look at ISAAC and other studies]]></article-title>
<source><![CDATA[Rev Alerg Mex.]]></source>
<year>2017</year>
<volume>64</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>188-97</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neffen]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Fritscher]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Schacht]]></surname>
<given-names><![CDATA[FC.]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Chiarella]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[JB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey]]></article-title>
<source><![CDATA[Rev Panam Salud Publica]]></source>
<year>2005</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>191-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zeiger]]></surname>
<given-names><![CDATA[RS.]]></given-names>
</name>
<name>
<surname><![CDATA[Schatz]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Dalal]]></surname>
<given-names><![CDATA[AA.]]></given-names>
</name>
<name>
<surname><![CDATA[Qian]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Ngor]]></surname>
<given-names><![CDATA[EW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilization and costs of severe uncontrolled asthma in a managed-care setting]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract.]]></source>
<year>2016</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>120-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reddel]]></surname>
<given-names><![CDATA[HK.]]></given-names>
</name>
<name>
<surname><![CDATA[FitzGerald]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
<name>
<surname><![CDATA[Bateman]]></surname>
<given-names><![CDATA[ED.]]></given-names>
</name>
<name>
<surname><![CDATA[Bacharier]]></surname>
<given-names><![CDATA[LB.]]></given-names>
</name>
<name>
<surname><![CDATA[Becker]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Brusselle]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents]]></article-title>
<source><![CDATA[Eur Respir J.]]></source>
<year>2019</year>
<volume>53</volume>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[PW.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
<name>
<surname><![CDATA[Bilir]]></surname>
<given-names><![CDATA[SP.]]></given-names>
</name>
<name>
<surname><![CDATA[Dang]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Kavati]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States]]></article-title>
<source><![CDATA[Curr Med Res Opin.]]></source>
<year>2020</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23-32</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serpa]]></surname>
<given-names><![CDATA[FS.]]></given-names>
</name>
<name>
<surname><![CDATA[Piana]]></surname>
<given-names><![CDATA[MP.]]></given-names>
</name>
<name>
<surname><![CDATA[Braga Neto]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Campinhos]]></surname>
<given-names><![CDATA[FL.]]></given-names>
</name>
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[MG. da]]></given-names>
</name>
<name>
<surname><![CDATA[Chiabai]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of anti-IgE therapy for asthma control]]></article-title>
<source><![CDATA[Braz J Allergy Immunol.]]></source>
<year>2014</year>
<volume>2</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>147-53</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[AM.]]></given-names>
</name>
<name>
<surname><![CDATA[Roncada]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Heinzmann-Filho]]></surname>
<given-names><![CDATA[JP.]]></given-names>
</name>
<name>
<surname><![CDATA[de Souza]]></surname>
<given-names><![CDATA[RG.]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[MHM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínicas de crianças e adolescentes Brasileiros com asma grave resistente a terapia]]></article-title>
<source><![CDATA[J Bras Pneumol.]]></source>
<year>2015</year>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>343-50</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Carvalho-Pinto]]></surname>
<given-names><![CDATA[RM.]]></given-names>
</name>
<name>
<surname><![CDATA[Agondi]]></surname>
<given-names><![CDATA[RC.]]></given-names>
</name>
<name>
<surname><![CDATA[Giavina-Bianchi]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Cukier]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Stelmach]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumabe em pacientes com asma grave não controlada: critérios de elegibilidade bem definidos para promover o controle da asma]]></article-title>
<source><![CDATA[J Bras Pneumol.]]></source>
<year>2017</year>
<volume>43</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>487-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giubergia]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Farías]]></surname>
<given-names><![CDATA[MJ.]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Crespi]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Castaños]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impacto clínico del tratamiento con omalizumab en niños con asma grave. Reporte de una experiencia local]]></article-title>
<source><![CDATA[Arch Argent Pediatr.]]></source>
<year>2019</year>
<volume>117</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>e115-20</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergna]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Braunstahl]]></surname>
<given-names><![CDATA[GJ.]]></given-names>
</name>
<name>
<surname><![CDATA[Canvin]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Peachey]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[CW.]]></given-names>
</name>
<name>
<surname><![CDATA[Georgiou]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Impacto del tratamiento con omalizumab sobre los costos indirectos y la utilización de recursos en pacientes con asma alérgica]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Argentina ]]></publisher-loc>
<publisher-name><![CDATA[Asociación Argentina de Medicina Respiratoria]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herrera]]></surname>
<given-names><![CDATA[AM.]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Perillán]]></surname>
<given-names><![CDATA[JA.]]></given-names>
</name>
<name>
<surname><![CDATA[Lezana]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Marinovic]]></surname>
<given-names><![CDATA[MA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab treatment on severe asthma patients: pediatric experience in Chile and literature review]]></article-title>
<source><![CDATA[Rev Chil Enferm Respir.]]></source>
<year>2016</year>
<volume>32</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>160-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales-Múnera]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Pedraza]]></surname>
<given-names><![CDATA[Á.]]></given-names>
</name>
<name>
<surname><![CDATA[Niño-Serna]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab in children with uncontrolled asthma: a real-life study carried out in Colombia]]></article-title>
<source><![CDATA[Rev Alerg Mex.]]></source>
<year>2018</year>
<volume>65</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>142-52</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vargas-Correa]]></surname>
<given-names><![CDATA[JB.]]></given-names>
</name>
<name>
<surname><![CDATA[Bracamonte-Peraza]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa-Morales]]></surname>
<given-names><![CDATA[SM.]]></given-names>
</name>
<name>
<surname><![CDATA[Vázquez-Nava]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical experience with omalizumab in patients with severe asthma. Real-world data]]></article-title>
<source><![CDATA[Rev Alerg Mex.]]></source>
<year>2016</year>
<volume>63</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>216-26</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herrera-García]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab en el tratamiento del asma moderada a grave persistente en el contexto de asma alérgica y no alérgica]]></article-title>
<source><![CDATA[Med Int Mex.]]></source>
<year>2015</year>
<volume>31</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>693-700</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Normansell]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Milan]]></surname>
<given-names><![CDATA[SJ.]]></given-names>
</name>
<name>
<surname><![CDATA[Walters]]></surname>
<given-names><![CDATA[EH.]]></given-names>
</name>
<name>
<surname><![CDATA[Nair]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab for asthma in adults and children]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev.]]></source>
<year>2014</year>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norman]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Faria]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Paton]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Llewellyn]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation]]></article-title>
<source><![CDATA[Health Technol Assess]]></source>
<year>2013</year>
<volume>17</volume>
<numero>52</numero>
<issue>52</issue>
<page-range>1-342</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casale]]></surname>
<given-names><![CDATA[TB.]]></given-names>
</name>
<name>
<surname><![CDATA[Luskin]]></surname>
<given-names><![CDATA[AT.]]></given-names>
</name>
<name>
<surname><![CDATA[Busse]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Zeiger]]></surname>
<given-names><![CDATA[RS.]]></given-names>
</name>
<name>
<surname><![CDATA[Trzaskoma]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract.]]></source>
<year>2019</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>156-64</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
